THE most frequently reported adverse reactions to both the Pfizer-BioNTech and AstraZeneca COVID-19 vaccinations (COVAX) in Australia remain in line with those seen in clinical trials, the latest data from the Therapeutic Goods Administration (TGA) reveals.
In the week to 16 May, a total of 1,860 adverse events following immunisation (AEFI) were reported to the TGA, including six cases of blood clots with low blood platelets, which have been assessed as thrombosis with thrombocytopenia syndrome (TTS) likely to be linked to the AstraZeneca vaccine.
The regulator said diarrheoa and vomiting have been added to the product information for the Pfizer vaccine based on international reports.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 May 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 May 21
